Randolf Kerschbaumer

Antibody conjugates have made blockbuster drugs in the ADC world and show promise to the radiopharmaceuticals field. While there are a large range of targets that can be addressed by antibodies, challenges in radiolabeling and biological halflife remain. Pre-targeting strategies may help unlock targeting specificity while matching biological half-life.

Join this interactive workshop to:

• Discuss Zevalin and Bexxar, previous antibody-based drugs, their efficacy and wider contextual and commercial factors
• Sharing novel prosthetic click-linker technologies
• Outlining radiolabeling strategies
• Exploring how to best match biological half-life with isotope half life
• Sharing pre-targeting strategies